Company: YCY-WT
Filing Date: 2025-07-09
Form Type: DRS
Source: 0001213900-25-062426
Chunk: 395

Company: AA Mission Acquisition Corp. II
Filing Date: 2025-07-09
Form: DRS
Chunk 395
---
,000 founder shares. Such securities were issued in connection with our organization pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 11,500,000 units if the underwriters’ over -allotmentoption is exercised in full and therefore that such founder shares would represent approximately 20% of the outstanding shares after this offering. Up to 375,000 of these shares will be forfeited depending on the extent to which the underwriters’ over -allotmentis exercised. AA Mission Sponsor II, our sponsor, is the record holder of the shares reported herein. Qing Sun, our Chief Executive Officer, is the sole manager of our sponsor and has voting and investment discretion with respect to the securities held of record by our sponsor and may be deemed to have beneficial ownership of the securities held directly by our sponsor. Our sponsor is an accredited investor for purposes of Rule 501 of Regulation D. Each of the equity holders in our sponsor is an accredited investor under Rule 501 of Regulation D. The sole business of our sponsor is to

II-1 act as the company’s sponsor in connection with this offering. The limited liability company agreement of our sponsor provides that its membership interests may only be transferred to our officers or directors or other persons affiliated with our sponsor, or in connection with estate planning transfers. The placement unit purchaser has committed to purchase an aggregate of 334,000 private placement units (or up to 360,250 private placement units if the underwriters’ over -allotmentoption is exercised in full), at a price of $10.00 per unit, for an aggregate purchase price of $3,340,000 (or up to $3,602,500 if the underwriters’ over -allotmentoption is exercised in full), in a private placement that will close simultaneously with the closing of this offering. This purchase will take place on a private placement basis simultaneously with the completion of our initial public offering. This issuance will be made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. No underwriting discounts or commissions were paid with respect to such sales. Item 16. Exhibits and Financial Statement Schedules (a)Exhibits.The list of exhibits following the signature page of this registration statement is incorporated herein by reference. (b)Financial Statements.See page F -1for an